Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.phrs.2022.106201
Title: COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
Authors: Ho, Wei Shen 
Zhang, Ruirui 
Tan, Yeong Lan 
Chai, Christina Li Lin 
Keywords: Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
Antivirals
COVID-19
Small molecule therapeutics
Drug discovery
Chloroquine (PubChem CID
2719)
Ivermectin (PubChem CID
6321424)
Lopinavir (PubChem CID
92727)
Ritonavir (PubChem CID
392622)
Remdesivir (PubChem CID
121304016)
Dexamethasone (PubChem CID
5743)
Baricitinib (PubChem CID
44205240)
Molnupiravir (Pubchem CID
145996610)
Nirmatrelvir (PubChem CID
155903259)
Chemical compounds studied in this article
Hydroxychloroquine (PubChem CID
3652)
ACUTE RESPIRATORY SYNDROME
IN-VITRO
LOPINAVIR-RITONAVIR
EBOLA-VIRUS
IVERMECTIN
INHIBITORS
CHLOROQUINE
EFFICACY
REMDESIVIR
DRUG
Issue Date: 1-May-2022
Publisher: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
Citation: Ho, Wei Shen, Zhang, Ruirui, Tan, Yeong Lan, Chai, Christina Li Lin (2022-05-01). COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?. PHARMACOLOGICAL RESEARCH 179. ScholarBank@NUS Repository. https://doi.org/10.1016/j.phrs.2022.106201
Abstract: The coronavirus disease 2019 (COVID-19) pandemic had grounded the world to a standstill. As the disease continues to rage two years on, it is apparent that effective therapeutics are critical for a successful endemic living with COVID-19. A dearth in suitable antivirals has prompted researchers and healthcare professionals to investigate existing and developmental drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some of these drugs initially appeared to be promising for the treatment of COVID-19, they were ultimately found to be ineffective. In this review, we provide a retrospective analysis on the merits and limitations of some of these drugs that were tested against SARS-CoV-2 as well as those used for adjuvant therapy. While many of these drugs are no longer part of our arsenal for the treatment of COVID-19, important lessons can be learnt. The recent inclusion of molnupiravir and Paxlovid™ as treatment options for COVID-19 represent our best hope to date for endemic living with COVID-19. Our viewpoints on these two drugs and their prospects as current and future antiviral agents will also be provided.
Source Title: PHARMACOLOGICAL RESEARCH
URI: https://scholarbank.nus.edu.sg/handle/10635/226977
ISSN: 10436618
10961186
DOI: 10.1016/j.phrs.2022.106201
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
COVID-19 and the promise of small molecule therapeutics Are there lessons to be learnt.pdfPublished version4.33 MBAdobe PDF

CLOSED

None

SCOPUSTM   
Citations

5
checked on Oct 1, 2022

Page view(s)

54
checked on Sep 29, 2022

Download(s)

1
checked on Sep 29, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.